FDA Now Finds NDMA Impurity In Heartburn Meds, Including Zantac

By Beth Wang / September 13, 2019 at 4:04 PM
FDA warned patients and health care professionals on Friday (Sept. 13) that it has discovered low levels of a carcinogenic impurity in some over-the-counter and prescription heartburn and indigestion drugs. The carcinogen, N-nitrosodimethylamine (NDMA), is one of the nitrosamine impurities that is the focus of FDA’s separate investigation into contaminated blood pressure and heart failure medicines. On Friday, FDA drug center director Janet Woodcock issued a statement saying some ranitidine medicines, which include the brand drug Zantac, contain NDMA at...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.